Seres Therapeutics (MCRB) H.C. Wainwright 28th Annual Global Investment Conference summary

Technology and innovation

• Developed a platform harnessing therapeutic potential of microbes and their metabolites, integrating AI for target identification and drug optimization.

• Achieved two FDA breakthrough therapy designations and pioneered the first FDA-licensed biotherapeutic for Clostridium difficile.

• Demonstrated ability to target the mucosal epithelial barrier, a unique disease-relevant interface.

Clinical programs and results

• Focused on oncology, inflammatory, and immune diseases with two phase II-ready programs using optimized bacterial consortia for oral delivery.

• SER-155 showed a 77% reduction in bloodstream infections in stem cell transplant patients, with placebo-like safety and reduced healthcare utilization.

• Achieved 80% immunosuppressor-free clinical response in immune-related enterocolitis, with several patients reaching clinical remission.

• Inflammatory bowel disease program aims to improve response rates and identify biomarkers for non-responders, with preclinical data supporting combination therapy efficacy.

Strategic direction and future plans

• Plans to partner phase II-ready stem cell transplant and irEC programs, while seeking capital for earlier-stage assets.

• IND-enabling studies ongoing for SER-603, with drug candidate nomination anticipated this year.

• Emphasizes targeting the root cause of disease by repairing the epithelial barrier, operating upstream of current immunosuppressive therapies.